There are currently 103 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are North Carolina, New York, California and Georgia.
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563
Recruiting
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
05/14/2024
Locations: Columbia University Medical Center, New York, New York +5 locations
Conditions: Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Anemia, Sickle Cell Disease
Register for Updates
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT05736419
Recruiting
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how... Read More
Gender:
All
Ages:
Between 2 years and 50 years
Trial Updated:
05/08/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey +5 locations
Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Register for Updates
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
NCT01499888
Recruiting
The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy in patients with aggressive sickle cell disease who are not candidates for or experienced complications from hydroxyurea therapy. Fully HLA matched siblings will be used as donors for hematopoietic stem cells to... Read More
Gender:
All
Ages:
Between 16 years and 60 years
Trial Updated:
05/06/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Sickle Cell Disease
Register for Updates
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
NCT06023199
Recruiting
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2024
Locations: Inova Schar Cancer Institute, Falls Church, Virginia
Conditions: Sickle Cell Disease
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Blood Collection for Research Related to Certain Diseases Involving Blood Vessels
NCT00047996
Recruiting
The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed....
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Sickle Cell Disease
Register for Updates
SMYLS Multi-site Trial
NCT06035939
Recruiting
The purpose of this study is to find out whether a web-based intervention using a mobile app is helpful for teens and young adults with sickle cell disease (SCD) in learning how to care for and manage their symptoms.
Gender:
All
Ages:
Between 14 years and 21 years
Trial Updated:
04/25/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Sickle Cell Disease
Register for Updates
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
NCT06385886
Recruiting
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assess... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Alabama, Birmingham (UAB), Birmingham, Alabama +3 locations
Conditions: Sickle Cell Disease
Register for Updates
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058
NCT05169580
Recruiting
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FTX-6058 in participants with sickle cell disease.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: Foundation for Sickle Cell Disease Research, LLC, Hollywood, Florida +9 locations
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659
Recruiting
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Gender:
All
Ages:
Between 12 years and 65 years
Trial Updated:
04/12/2024
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +86 locations
Conditions: Sickle Cell Disease
Register for Updates
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
NCT04839354
Recruiting
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
04/12/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California +9 locations
Conditions: Sickle Cell Disease
Register for Updates
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
NCT04930445
Recruiting
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
Gender:
All
Ages:
4 years and above
Trial Updated:
04/10/2024
Locations: University of South Alabama, Mobile, Alabama +40 locations
Conditions: Sickle Cell Disease
Register for Updates